(NASDAQ: NTLA) Intellia Therapeutics's forecast annual revenue growth rate of 29.44% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.22%, and while it is forecast to beat the US market's average forecast revenue growth rate of 9.95%.
Intellia Therapeutics's revenue in 2024 is $52,604,000.On average, 12 Wall Street analysts forecast NTLA's revenue for 2024 to be $7,021,867,042, with the lowest NTLA revenue forecast at $3,895,677,500, and the highest NTLA revenue forecast at $12,613,196,542. On average, 11 Wall Street analysts forecast NTLA's revenue for 2025 to be $8,329,398,423, with the lowest NTLA revenue forecast at $868,278,789, and the highest NTLA revenue forecast at $20,259,838,410.
In 2026, NTLA is forecast to generate $11,443,914,439 in revenue, with the lowest revenue forecast at $5,806,855,590 and the highest revenue forecast at $16,969,061,800.